These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 5337082)

  • 21. Modern views on pharmacology. VI. Peripheral cholinergic systems.
    Crossland J
    Practitioner; 1971 Jun; 206(236):836-42. PubMed ID: 4397252
    [No Abstract]   [Full Text] [Related]  

  • 22. [Role of cyclic AMP in neuromuscular transmission--with special reference to the effect of catecholamines, xanthines and calcium on myasthenic syndrome].
    Takamori M
    Rinsho Shinkeigaku; 1972 Oct; 12(10):520-8. PubMed ID: 4345472
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome.
    Maselli RA
    Neurol Clin; 1994 May; 12(2):285-303. PubMed ID: 8041343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cholinergic and adrenergic agents and their antagonists at the neuromuscular junction of the cat extraocular muscles.
    Sanghvi IS
    Invest Ophthalmol; 1967 Jun; 6(3):269-76. PubMed ID: 5338178
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome.
    Lindstrom J
    Annu Rev Immunol; 1985; 3():109-31. PubMed ID: 2998417
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effects of so-called "depolarizing" and "repolarizing" substances on neuromuscular excitability].
    Quevauviller A; Levy JC
    Anesth Analg (Paris); 1967; 24(2):247-68. PubMed ID: 4383825
    [No Abstract]   [Full Text] [Related]  

  • 27. Proceedings: Drug concentration-conductance curves at frog end-plates determined by voltage-clamp.
    Adams PR
    J Physiol; 1974 Aug; 241(1):7P-8P. PubMed ID: 4419357
    [No Abstract]   [Full Text] [Related]  

  • 28. [Neuromuscular transmission in patients with myasthenia gravis treated by plasmapheresis and hemosorption].
    Marshaniia ZS; Sanadze AG; Kil'diushevskiĭ AV; Startsev AI
    Klin Med (Mosk); 1987 Jul; 65(7):107-10. PubMed ID: 2822998
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prolonged neuromuscular blockade during a D. penicillamine-induced myasthenia (author's transl)].
    Blanloeil Y; Baron D; Gazeau MF; Nicolas F
    Anesth Analg (Paris); 1980; 37(7-8):441-3. PubMed ID: 7425327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of sugammadex in a patient with myasthenia gravis.
    Unterbuchner C; Fink H; Blobner M
    Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sites of action of gerine diacetate in myasthenia gravis.
    Flacke W; Caviness VS; Samaha F; Schwab RS
    Trans Am Neurol Assoc; 1967; 92():158-62. PubMed ID: 5634017
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of adrenergic neurotransmission by parasympathomimetics in the rabbit ear artery.
    Steinsland OS; Furchgott RF; Kirpekar SM
    J Pharmacol Exp Ther; 1973 Feb; 184(2):346-56. PubMed ID: 4347257
    [No Abstract]   [Full Text] [Related]  

  • 33. The neuromuscular pharmacology of germine-3-acetate and germine-3,16-diacetate.
    Standaert FG; Detwiler PB
    J Pharmacol Exp Ther; 1970 Feb; 171(2):223-41. PubMed ID: 5459059
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of hemosorption on the status of neuromuscular transmission in myasthenia].
    Marshaniia ZS; Sanadze AG; Startsev AI
    Sov Med; 1986; (11):16-9. PubMed ID: 3031823
    [No Abstract]   [Full Text] [Related]  

  • 35. [Problems of antibiotic administration in myasthenia gravis].
    Onishi A; Shida K; Kuroiwa Y
    Shinkei Kenkyu No Shimpo; 1971; 15(4):906-10. PubMed ID: 4334475
    [No Abstract]   [Full Text] [Related]  

  • 36. Observations of transduced mandibular movements with cholinergic drugs in myoneural junction disease.
    Zafran JN; Zayon GM; Spector S
    Oral Surg Oral Med Oral Pathol; 1968 Aug; 26(2):237-43. PubMed ID: 5242056
    [No Abstract]   [Full Text] [Related]  

  • 37. Activation and inactivation of muscle postjunctional receptors.
    Nastuk WL
    Fed Proc; 1967; 26(6):1639-46. PubMed ID: 6075903
    [No Abstract]   [Full Text] [Related]  

  • 38. [The effect of Amaryllidaceae alkaloids galanthamine, narwedine, hemanthamine and tazettine on neuromuscular transmission].
    LIEBMANN H; MATTHIES H
    Acta Biol Med Ger; 1961; 7():411-9. PubMed ID: 14465193
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of myasthenia gravis.
    Saperstein DS; Barohn RJ
    Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathogenesis and pathophysiology of myasthenia gravis--electrophysiological, ultrastructural and immunological aspects of neuromuscular junctions (author's transl)].
    Takamori M; Tsujihata M; Ide Y; Eguchi K; Mine M
    No To Shinkei; 1980 Sep; 32(9):891-908. PubMed ID: 6254548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.